论文部分内容阅读
国际跨国医药企业在愁什么?无疑是已经迫在眉睫的专利到期问题。近两年在与国际医药公司的采访中不难体会到,他们都在为此筹划出路,尽可能的减少企业的损失。据了解,2001年到2010年,是世界制药史上药品专利到期的高峰时段,一些大型跨国制药公司陆续有一半以上的药品专利到期,一大批单品种销售额超过10亿美元的药品专利保护期也已届满。
International multinational pharmaceutical companies in worry what? Undoubtedly the imminent patent expiration issues. In the past two years, it is not hard to realize in interviews with international pharmaceutical companies that they are all planning a way out to minimize the losses of their enterprises. It is understood that from 2001 to 2010, is the peak of the expiration of drug patents in the world pharmaceutical history, a number of large multinational pharmaceutical companies have more than half of the drug patents expire, a large number of single species with sales of more than 1 billion US dollars in pharmaceutical patents The term of protection has also expired.